REFERENCES
- Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev. 2005;4:510–518.
- Dawson IC, Beck MA, Kuziel WA, Henderson F, Maeda N. Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus. Am J Pathot 2000;156: 1951–1959.
- Idemyor V. Human immunodeficiency virus (HIV) entry in-hibitors (CCR5 specific blockers) in development: are they the next novel therapies? HIV Clin Trials. 2005; 6:272–277.
- Lim JK, Glass WG, McDermott DH, Murphy PM. CCR5: no longer a "good for nothing" gene-chemokine control of West Nile virus infection. Trends Immunot 2006; 27:308–312.
- Sorensen LN, Paludan SR. Blocking CC chemokine recep-tor (CCR) 1 and CCR5 during herpes simplex virus type 2 infection in vivo impairs host defence and perturbs the cytokine response. Scand J Immunot 2004;59:321–333.
- Carr DJ, Ash J, Lane TE, Kuziel WA. Abnormal immune response of CCR5-defecient mice to ocular infection with herpes simplex virus type 1 / aen Vim! 2006;87: 489–499.
- Algood HM, Flynn JL. CCR5-deficient mice control Myco-bacterium tuberculosis infection despite increased pulmo-nary lymphocytic infiltration. J Immunot 2004;173:3287–3296.
- Takeuchi A, Usui Y, Takeuchi M, et al. CCR5-deficient mice develop experimental autoimmune uveoretinitis in the con-text of a deviant effector response. Invest Ophthalmol Vis Sci. 2005;46:3753–3760.
- Murooka TT, Wong MM, Rahbar R, Majchrzak-Kita B, Proudfoot AE, Fish EN. CCL5-CCR5 mediated apoptosis in T cells: requirement for glycosaminoglycan binding and CCL5 aggregation. J Biol Chem. 2006; Jun 28; [Epub ahead of print].
- Wysocki CA, Jang Q, Panoskaltsis-Moitari A, et al. Critical role for CCR5 in the function of donor CD4+CD25+ regula-tory T cells during acute graft-versus-host disease. Blood. 2005;106: 3300–3307.
- Seifaith C, Mack M, Steinlicht S, Hahn EG, Lohmann T. Transient chemokine receptor blockade does not prevent, but may be accelerate type 1 diabetes in prediabetic NOD mice. Horm Metab Res. 2006;38: 167–171.
- Deeks SG. Challenges of developing R5 inhibitors in antiretroviral naïve HIV-infected patients. Lancet. 2006;367:711–713.
- Jaeckel E, Manns M, Herrath MV. Viruses and diabetes. Ann NY Acad Sci. 2002;958:7–25.
- Hogancamp WE, Rodriguez M, Weinshenker BG. The epi-demiology of multiple sclerosis. Mayo Clin Proc. 1997;27:871–878.
- Pulkkinen K, Luomala M, Kuusisto H, et al. Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis. Acta Neurol Scand. 2004;109:342–347.
- Favorova OO, Andreewski TV, Boiko AN, et al. The chemokine receptor CCR5 deletion mutation is associated with MS in HLA-DR4-positive Russians. Neurology. 2002;59: 1652–1655.
- Mojtahedi Z, Baharvand-Ahmadi S, Razmkhah M, Khalili-Azade T, Rajaee A, Ghaderi A. Association of chemokine receptor 5 (CCR5) 432 mutation with Behcet's disease is dependent on gender in Iranian patients. Clinc Exp Rheumatot In press.